z-logo
open-access-imgOpen Access
The diagnostic efficacy of whole body 18F-FDG PET CT in detection of unexpected second primary malignancy in cancer patients
Author(s) -
Susan Adil Ali,
Maged Abd Elgalil Hamed
Publication year - 2017
Publication title -
the egyptian journal of radiology and nuclear medicine /the egyptian journal of radiology and nuclear medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.19
H-Index - 13
eISSN - 2090-4762
pISSN - 0378-603X
DOI - 10.1016/j.ejrnm.2017.01.017
Subject(s) - medicine , malignancy , cancer , primary tumor , radiology , nuclear medicine , positron emission tomography , primary cancer , metastasis
Purpose: to assess the efficacy of FDG PET/CT in detecting unexpected additional primary malignant neoplasms in patients being evaluated by PET/CT for known malignancies compared to conventional staging work-up (CSW). Patients and methods: Of 1889 patients referred for whole-body FDG PET/CT in the period from February 2015 to May 2016, only 273 were included in this prospective study. Patients included are those with histopathologicaly proven primary malignancy and sent for initial tumor staging before treatment within 1 month of CSW that was performed for the patients according to the site and cell type of the primary tumor. Histopathologic examination was performed for lesions indicating additional primary cancer detected by either PET/CT or CSW. Results: In 13 out of 273 patients included in the study (4.76%) only were proved to have additional primary cancer, the PPV of PET/CT for detecting an additional primary cancer was 56.5%. Also, it showed high sensitivity of 89.2%, which was significantly higher than 23% from the CSW (P < 0.005). Conclusion: PET/CT is more accurate than CSW for detecting additional primary cancer with a higher sensitivity and positive predictive value, which consequently affect further management. Keywords: PET/CT, Second primary malignanc

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here